Galectin Therapeutics (GALT) Other Non-Current Liabilities (2010 - 2026)
Galectin Therapeutics' quarterly Other Non-Current Liabilities came in at $3.0 million in Q1 2026, up 2090.44% year-on-year from $136000.0 in Q1 2025, and down 24.81% quarter-over-quarter from $4.0 million in Q4 2025.
Galectin Therapeutics has reported Other Non-Current Liabilities for 12 years, with the latest figure at $3.0 million in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Liabilities rose 2090.44% year-over-year to $3.0 million; the trailing twelve-month figure through Mar 2026 stood at $3.0 million (up 2090.44% YoY), and the FY2025 full-year result was $4.0 million, up 8329.79% from the prior year.
- Other Non-Current Liabilities for Q1 2026 stood at $3.0 million, down from $4.0 million in the prior quarter.
- The five-year high for Other Non-Current Liabilities was $4.0 million in Q4 2025, with the low at $47000.0 in Q4 2024.
- Average Other Non-Current Liabilities over 5 years is $773312.5, with a median of $291500.0 recorded in 2022.
- Year-over-year, Other Non-Current Liabilities slumped 88.37% in 2024 and surged 8329.79% in 2025.
- Tracing GALT's Other Non-Current Liabilities over 5 years: stood at $214000.0 in 2022, then jumped by 88.79% to $404000.0 in 2023, then tumbled by 88.37% to $47000.0 in 2024, then surged by 8329.79% to $4.0 million in 2025, then slipped by 24.81% to $3.0 million in 2026.
- The last three Other Non-Current Liabilities figures came in at $3.0 million (Q1 2026), $4.0 million (Q4 2025), and $1.5 million (Q2 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn |
| 10 | Galectin Therapeutics | 165.77 Mn | 151.67 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.98 Mn |
| Dec 31, 2025 | 3.96 Mn |
| Jun 30, 2025 | 1.54 Mn |
| Mar 31, 2025 | 136,000.00 |
| Dec 31, 2024 | 47,000.00 |
| Sep 30, 2024 | 1.20 Mn |
| Jun 30, 2024 | 666,000.00 |
| Mar 31, 2024 | 688,000.00 |
| Dec 31, 2023 | 431,000.00 |
| Sep 30, 2023 | 600,000.00 |
| Jun 30, 2023 | 159,000.00 |
| Mar 31, 2023 | 479,000.00 |
| Dec 31, 2022 | 109,000.00 |
| Sep 30, 2022 | 301,000.00 |
| Jun 30, 2022 | 131,000.00 |
| Mar 31, 2022 | 276,000.00 |
| Dec 31, 2021 | 495,000.00 |
| Sep 30, 2020 | 19,000.00 |
| Jun 30, 2020 | 31,000.00 |
| Mar 31, 2020 | 42,000.00 |
| Dec 31, 2019 | 52,000.00 |
| Sep 30, 2019 | 62,000.00 |
| Jun 30, 2019 | 72,000.00 |
| Mar 31, 2019 | 81,000.00 |
| Sep 30, 2013 | 1,000.00 |
| Jun 30, 2013 | 5,000.00 |
| Mar 31, 2013 | 5,000.00 |
| Dec 31, 2012 | 6,000.00 |
| Jun 30, 2011 | 3,000.00 |
| Dec 31, 2010 | 12,000.00 |